Zhen-Ao says long-term research is key to healthy aging

At Summer Davos in Dalian, Zhen-Ao Group CEO Xu Bin said China should use openness, innovation and cooperation to help address healthy aging worldwide. He said long-term research, measurable evidence and scalable solutions are essential as global trade and technology barriers rise.

Why it matters: - Healthy aging is becoming a global business and public-health priority as populations age in China and elsewhere. - Zhen-Ao Group is positioning nucleic-acid nutrition and biological-age research as part of the answer. - Xu Bin argued that durable scientific evidence matters more than broad claims in an industry often driven by marketing.

What happened: - Xu Bin, Party Secretary and CEO of Zhen-Ao Group, spoke to media on the sidelines of the 2026 Annual Meeting of the New Champions in Dalian. - The forum, known as Summer Davos, is meeting under the theme “Innovating at Scale.” - Xu said Premier Li Qiang’s opening remarks signaled that China intends to keep pursuing openness, innovation and cooperation despite geopolitical tensions and trade fragmentation. - Xu said Zhen-Ao wants to contribute “happy longevity solutions from China” focused on healthspan, quality of life and everyday wellbeing.

The details: - Zhen-Ao was founded in 1996 and is based in Dalian. - The company has spent nearly 30 years focused on nucleic-acid nutrition and 5'-nucleotide-related research. - Zhen-Ao said it has built a full-chain evidence system covering molecular mechanisms, cellular function, animal models and human clinical research. - The company has also developed a nucleic-acid industrialization base in Dalian. - Zhen-Ao said it has supported long-term studies on safety, healthy aging and biological-age indicators. - Company materials say Zhen-Ao has produced 21 academic papers and 15 domestic and international invention patents. - In one randomized, double-blind, controlled human intervention study of 121 people ages 60 to 70, 19 weeks of 5'-nucleotide supplementation was associated with a 3.08-year reduction in DNA methylation age versus the control group. - A multi-omics analysis of the same study population reported a 5.1-year reduction in biological age among participants with high genetic risk of hyperuricemia. - Xu said China’s role in the global economy is shifting from being seen mainly as the “world factory” to a “world solutions base.”

Between the lines: - Xu is tying Zhen-Ao’s research strategy to a larger argument about China’s place in global innovation. - The message also frames healthy aging as an area where Chinese companies can compete through evidence, not just scale. - Xu’s remarks suggest that Chinese private firms are trying to move from manufacturing-led growth to original research and global collaboration. - The company’s emphasis on measurable biological-age data signals a push to make longevity claims more defensible and more exportable. - Xu said the response to uncertainty is not isolation but more balanced, resilient and practical cooperation.

What’s next: - Zhen-Ao plans to deepen its work in healthy aging. - The company also plans broader cooperation with research institutions, medical organizations and industry partners. - Xu said the company wants to keep linking Chinese research with global dialogue as the forum’s discussions continue. - Premier Li’s message, Xu said, points to the future direction of global cooperation.